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In Brief
Young et al. show that Sphk1 facilitates
endocytic trafficking. Inhibition of Sphk1
with a lipid-based inhibitor or in the
presence of sphingosine accumulates
enlarged, dysfunctional late endosomes
that impair autophagy. The autophagic
machinery coordinates with lysosomal
biogenesis to restore endocytic
trafficking, thus highlighting crosstalk
between autophagy, sphingolipids, and
endocytosis.
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Sphingosine kinase 1 (Sphk1) associates with early
endocytic membranes during endocytosis; however,
the role of sphingosine or sphingosine-1-phosphate
as the critical metabolite in endocytic trafficking
has not been established. Here, we demonstrate
that the recruitment of Sphk1 to sphingosine-
enriched endocytic vesicles and the generation of
sphingosine-1-phosphate facilitate membrane traf-
ficking along the endosomal pathway. Exogenous
sphingosine and sphingosine-based Sphk1 inhibi-
tors induce the Sphk1-dependent fusion of endoso-
mal membranes to accumulate enlarged late endo-
somes and amphisomes enriched in sphingolipids.
Interestingly, Sphk1 also appears to facilitate endo-
somal fusion independent of its catalytic activity,
given that catalytically inactive Sphk1G82D is re-
cruited to endocytic membranes by sphingosine or
sphingosine-based Sphk1 inhibitor and promotes
membrane fusion. Furthermore, we reveal that the
clearance of enlarged endosomes is dependent on
the activity of ceramide synthase, lysosomal biogen-
esis, and the restoration of autophagic flux. Collec-
tively, these studies uncover intersecting roles for
Sphk1, sphingosine, and autophagic machinery in
endocytic membrane trafficking.INTRODUCTION
Sphingolipids are a class of inter-convertible, bioactive lipids
that have dynamic functions in cellular signaling and membrane
composition. Sphingosine kinase (Sphk) catalyzes the conver-
sion of pro-apoptotic sphingosine (Sph) to pro-survival sphingo-
sine-1-phosphate (S1P) (Hannun andObeid, 2008). In addition to
cellular signaling, Sphk modulates membrane dynamics by con-
verting the largely membrane-restricted substrate Sph to soluble
S1P (Gon˜i et al., 2014). Sphingoid base metabolism also has
a conserved role in endocytosis, as it is required for yeast endo-
cytosis (Hannich et al., 2011), synaptic vesicle recycling in
D. melanogaster (Rohrbough et al., 2004) and C. elegans (Chan1532 Cell Reports 17, 1532–1545, November 1, 2016 ª 2016 The Au
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ficking in D. melanogaster photoreceptors (Acharya et al., 2003,
2004; Yonamine et al., 2011).
The regulation of membrane fusion events by Sph and S1P
was initially characterized in neurons during synaptic vesicle
exocytosis. The soleC. elegans isoform, sphk-1, localizes to pre-
synaptic terminals for the generation of S1P and recruitment of
the soluble N-ethylmaleimide-sensitive factor activating protein
receptor (SNARE) Munc13 for synaptic vesicle release (Chan
and Sieburth, 2012; Chan et al., 2012). Moreover, Sph alters
the local membrane environment to activate synaptobrevin for
SNARE complex assembly and membrane fusion (Darios et al.,
2009). Local accumulation of Sph also induces a conformational
change in the SNARE Syntaxin1 to enhance its interaction with
the docking molecule Munc18 and sequester synaptic vesicles
away from the active zone (Camoletto et al., 2009). As neuronal
and endocytic SNARE proteins are highly conserved in structure
and function (Antonin et al., 2000), we hypothesize that sphin-
goid base metabolism regulates membrane fusion events in
the endocytic pathway. Indeed, knockdown of both mammalian
Sphk isoforms impairs transferrin uptake and recycling to sug-
gest a conserved function in endocytosis (Shen et al., 2014).
While Sphk1 recruitment to early endocytic intermediates has
recently been reported, the identification of Sph or S1P as
the important metabolite in this process has not been firmly
established.
The endocytic pathway converges with the highly conserved
cellular recycling pathway of autophagy. During autophagy,
damaged proteins and/or organelles are engulfed within dou-
ble-membrane vesicles known as autophagosomes and deliv-
ered to late endosomes (LEs) and/or lysosomes (Lys) for degra-
dation (Amaya et al., 2015). Autophagy is regulated by over 30
identified autophagy-related genes (Atgs) (Feng et al., 2014). Au-
tophagic degradation requires functional LEs and Lys; thus, it is
not surprising that several components of the autophagic ma-
chinery positively regulate the endocytic pathway (Lamb et al.,
2013), including Beclin1 (Liang et al., 2008; Ruck et al., 2011),
Atg14L (Kim et al., 2012), Atg5 (Peng et al., 2014), and Atg3 (Mur-
row et al., 2015). Bidirectional crosstalk also occurs between
autophagy and sphingolipids, because sphingolipids positively
and negatively regulate autophagy (Young et al., 2013) and accu-
mulate in autophagy-deficient cells (Alexaki et al., 2014).
Here, we utilized exogenous Sph, Sphk1-selective inhibitors,
and genetic approaches to demonstrate a role for Sph andthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Sphk1 in endocytic membrane trafficking. Moreover, as the
autophagic machinery restores endocytic function in response
to disruption by a Sphk1-selective inhibitor, our studies validate
the importance of autophagy-related proteins in the mainte-
nance of endocytic trafficking.
RESULTS
The Sphk1-Selective Inhibitor and Sph Mimetic, SK1-I,
Impairs Endocytic Membrane Trafficking
Tools that allow for the study of dynamic changes in endogenous
sphingolipids within localized cellular membranes during endo-
cytosis remain to be established. Therefore, to investigate the
role of Sphk1 activity in endocytic trafficking, we utilized several
pharmacological inhibitors. Unexpectedly, Sph-based Sphk in-
hibitors SK1-I, N,N-dimethyl-sphingosine (DMS), and FTY720
induce the rapid appearance of dilated cytosolic structures
that we will call ‘‘vacuoles’’ (Figure 1A). Vacuolization is dose
and time dependent and occurs in transformed mouse embry-
onic fibroblasts (MEFs) as well as multiple cancer cell lines,
including HeLa cells (Figures 1A and S1A–S1C). In contrast to
macropinocytosis, the large vacuoles (>5 mm in diameter) arise
from the progressive fusion of small perinuclear vacuoles
(Movies S1 and S2). Interestingly, the Sph-based inhibitors
also generate small vacuoles in Sphk1-deficient MEFs; however,
these structures do not fuse upon prolonged monitoring to sug-
gest that vacuole enlargement is Sphk1 dependent (Figures 1A,
S1B, S1D, and S1E; Movies S3 and S4).
Strikingly, vacuoles are not observed under basal conditions
in Sphk1/ MEFs or upon Sphk1 inhibition by the potent,
small-molecule inhibitor PF-543 (Figure 1A). We hypothesize
that treatment with the Sph mimetics SK1-I, DMS, and FTY720
overloads endocytic membranes with Sph-like lipids to promote
Sphk1-dependent membrane fusion and vacuole formation.
Consistently, phosphorylated FTY720 fails to induce vacuole for-
mation, thus highlighting the importance of the Sph-like structure
(Figure S1F). Moreover, vacuolization occurs independently of
S1P receptor (S1PR) signaling, as pre-treatment with the S1PR
agonist FTY720-phosphate fails to alter vacuole formation by
FTY720 or SK1-I (Figure S1G).
Given that SK1-I is a Sphk1-selective inhibitor (Paugh et al.,
2008) and that Sphk1 is implicated in endocytosis (Shen et al.,
2014), we chose the isozyme-selective inhibitor for further study.
Consistent with a role in endocytic trafficking, the limiting mem-
branes of SK1-I-induced vacuoles contain the LE/Lys marker
Lamp1-RFP (red fluorescent protein) (Figure 1B). In contrast,
mitochondrial and endoplasmic reticulum structures remain
relatively intact (Figures S2A and S2B). To visualize fluid-phase
endocytosis, cells were co-treated with 10 kDa Alexa Fluor
488-dextran. Interestingly, basal fluid-phase endocytosis is not
altered by the loss of Sphk1, as the internalization and delivery
of fluorescent dextran to Lamp1-positive puncta is comparable
in wild-type (WT) and Sphk1/ cells (Figure 1B). In contrast,
inhibition of Sphk1 by SK1-I accumulates large Lamp1-positive
vacuoles containing fluorescent dextran, while treatment of
Sphk1/ cells moderately accumulates fluorescent dextran
puncta that are significantly smaller than the vacuoles ofWT cells
(Figure 1B).To confirm that the enlargement of SK1-I-induced vacuoles
is Sphk1 dependent, Sphk1 expression was rescued in Sphk1-
deficient MEFs (Figures 1C and 1D). Indeed, transient expres-
sion of EGFP-tagged murine Sphk1a significantly enlarges
SK1-I-induced Lamp1-positive vacuoles compared to EGFP
control (Figures 1D and 1E). Unexpectedly, EGFP-tagged
catalytically inactive Sphk1aG82D significantly enlarges SK1-I-
induced vacuoles (Figures 1D and 1E). EGFP-Sphk1a and
EGFP-Sphk1aG82D are both recruited to vacuole membranes
during SK1-I treatment and are present during vacuole fusion
(Figure 1D; Movie S5), leading us to hypothesize that Sphk1
can promote membrane fusion independent of its catalytic
activity. Collectively, these studies reveal that inhibition of
Sphk1 by SK1-I promotes LE/Lys fusion in a Sphk1-dependent
manner.
Sphk1 Activity Promotes Endocytic Membrane
Trafficking
Next, we attempted to mimic the effect of SK1-I by overloading
the endocytic pathway with a non-toxic dose of exogenous
sphingosine (Sph) in the presence of PF-543. Exogenous Sph in-
duces the dose-dependent formation of vacuoles in both WT
and Sphk1-deficient MEFs (Figures 2A and S2C). However, in
contrast to non-metabolizable SK1-I, Sph-induced vacuoles
rapidly disappear by 4 hr in WT cells (Figure 2B). Interestingly,
loss of Sphk1 or inhibition of Sphk1 by PF-543 significantly pro-
longs Sph-induced vacuoles to suggest a critical role for Sphk1
activity in restoring membrane trafficking in response to exoge-
nous Sph (Figures 2B, S2D, and S2E). Similar to SK1-I, Sph-in-
duced vacuoles are positive for Lamp1-RFP to indicate that
an overload of Sph blocks endocytic trafficking at LE/Lys
(Figure 2C).
To confirm the result using a genetic approach, EGFP-Sphk1a
or EGFP- Sphk1aG82D was transiently expressed in Sphk1-defi-
cient MEFs (Figures 1C and 2C). Indeed, EGFP- or EGFP-
Sphk1aG82D-expressing cells sustain Sph-induced vacuoles
compared to rescue cells expressing EGFP-Sphk1a (Figures
2C). Interestingly, the size of Sph-induced vacuoles is signifi-
cantly increased by EGFP-Sphk1aG82D compared to EGFP
control to once again suggest that recruitment of Sphk1 can
promote the fusion of Sph-containing endocytic membranes in-
dependent of its catalytic activity (Figures 2C and 2D). Taken
together, these results suggest a role for Sph and Sphk1 protein
in endosomal maturation.
Inhibition of Sphk1 by SK1-I Accumulates Enlarged Late
Endosomes and Amphisomes Enriched in Sphingolipids
As exogenous Sph is a substrate of several sphingolipid-metab-
olizing enzymes, we chose to utilize non-metabolizable SK1-I to
further characterize the endocytic defect. As the disruption of
lipid rafts at the plasma membrane recruits Sphk1 to early endo-
cytic intermediates (Shen et al., 2014), cells were briefly treated
with the cholesterol-depleting agent hydroxypropyl-b-cyclodex-
trin (HPbCD) prior to SK1-I. Interestingly, cellular vacuolization
and uptake of SK1-I were impaired by HPbCD to suggest that
the lipid-based inhibitor enters the cell by cholesterol-dependent
endocytosis (Figures S3A and S3B). Consistently, inhibition
of endocytosis by pre-treatment with the vacuolar ATPaseCell Reports 17, 1532–1545, November 1, 2016 1533
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Figure 1. The Sphk1-Selective Inhibitor and Sph Mimetic, SK1-I, Impair Endocytic Membrane Trafficking
(A) Representative phase-contrast images of wild-type (WT) and Sphk1/ MEFs treated with DMSO; 10 mM SK1-I, DMS, or FTY720; or 1 mM PF-543 for 6 hr.
(B) Live-cell fluorescence imaging ofWT andSphk1/MEFs stably expressing Lamp1-RFP (L1-RFP) co-treated with 100 mg/mL Alexa Fluor 488-dextran (AF488)
and DMSO or 7.5 mM SK1-I for 2 hr.
(C and D) Live-cell fluorescence images of Sphk1/ MEFs stably expressing Lamp1-RFP (L1-RFP) transiently transfected with EGFP, EGFP-Sphk1a (WT), or
EGFP-Sphk1aG82D (G82D) and treated with (C) DMSO or (D) 7.5 mM SK1-I for 4 hr. DIC, differential interference contrast.
(E) Vacuole size of (D) is presented as the mean ± SEM from three independent experiments. n > 400 vacuoles per treatment. ****p < 0.0001, ANOVA.
Scale bars represent 20 mm in (A), 10 mm in (B)–(D), and 5 mm in enlarged panels of (D). See also Figures S1 and S2 and Movies S1, S2, S3, S4, and S5.
1534 Cell Reports 17, 1532–1545, November 1, 2016
Sph
W
T
S
ph
k1
-/-
DMSO enlargedA B
D
PF-543
W
T
S
ph
k1
-/-
PF-543 Sph
en
la
rg
ed
+ SphDMSO
W
T
S
ph
k1
-/-
C
EGFP G82D
0
20
40
60
80
100
A
re
a 
pe
r
va
cu
ol
e 
(A
U
) ****
Sph
enlargedEGFP L1-RFP DIC merged
E
G
FP
G
82
D
W
T
Figure 2. Sphk1-Dependent Phosphorylation of Sphingosine Promotes Endocytic Membrane Trafficking
(A) Phase-contrast images of WT or Sphk1/ MEFs treated with DMSO or 10 mM sphingosine (Sph) for 1 hr.
(B) WT or Sphk1/ MEFs pre-treated with DMSO or 2.5 mM PF-543 for 30 min followed by DMSO or 10 mM Sph for an additional 4 hr.
(C) Sphk1/ MEFs stably expressing Lamp1-RFP (L1-RFP) transiently transfected with EGFP, EGFP-Sphk1G82D (G82D), or EGFP-Sphk1 (WT) plasmids and
treated with 7.5 mM Sph for 4 hr.
(D) Vacuole size of (C) is presented as the mean ± SEM from two independent experiments. n > 800 vacuoles per treatment. ****p < 0.0001, ANOVA.
Scale bars represent 20 mm in (A) and (B), 10 mm in (C) and enlarged panels of (B), and 5 mm in enlarged panels of (C). See also Figure S2.inhibitor, Bafilomycin A1 (BafA1), also impairs SK1-I-induced
vacuole formation (Figure S3A).
Consistent with a defect in endosomal trafficking, EEA1-pos-
itive early endosomes are slightly enlarged by SK1-I (Figure 3A).
While the large vacuoles contain the LE/Lys marker Lamp1-RFP,
the vacuoles are devoid of cathepsin B activity and fail to
accumulate the acidic probe LysoSensor to suggest impaired
function (Figures 3B and 3C). Moreover, the enlarged vacuoles
contain endogenous Lamp1 that colocalizes with LE marker
Rab7 and autophagymarker GFP-LC3 (Figure 3D). Transmission
electron microscopy (TEM) of SK1-I-treated cells reveals theaccumulation of massive endosomes containing intraluminal
vesicles (ILVs) that are indicative of LEs (Figures 3Ei and 3Eii).
Consistent with an accumulation of GFP-LC3, SK1-I-treated
cells accumulate large amphisome-like structures containing
ILVs in the presence of undigested cytoplasmic material to
suggest impaired autophagy (Figures 3Eiii and 3Eiv).
Next, we sought to investigate the sphingolipid profile of
the vacuoles. Consistent with previous reports (Kapitonov
et al., 2009; Paugh et al., 2008), SK1-I alters global sphingolipid
metabolism by decreasing cellular S1P and increasing sphin-
gosine, ceramide, monohexosylceramide, and sphingomyelinCell Reports 17, 1532–1545, November 1, 2016 1535
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Figure 3. Inhibition of Sphk1 by SK1-I Accumulates Stalled LEs and Amphisomes
(A) Fluorescence images of WT MEFs stably expressing Lamp1-RFP treated with 10 mM SK1-I for 6 hr and immunostained with anti-EEA1.
(B) Live-cell fluorescence images of WTMEFs co-treated with 100 mg/mL Alexa Fluor 488-Dextran (AF488-Dex) and 7.5 mMSK1-I for 4 hr, followed by MagicRed
cathepsin B substrate (MR-CathB).
(C) Live-cell fluorescence images of WT MEFs treated with 7.5 mM SK1-I for 4 hr, followed by labeling with LysoSensor DND-189.
(D) Confocal images of WTMEFs stably expressing GFP-LC3 treated with 7.5 mMSK1-I for 6 hr and immunostained using anti-Lamp1 (red) and anti-Rab7 (cyan).
(E) TEM images of WT MEFs treated with 10 mM SK1-I for 6 hr. LE, late endosome; A, amphisome. Dotted outline indicate cytoplasmic material; arrowheads
indicate intraluminal vesicles.
Scale bars represent 20 mm in (A), 10 mm in (B)–(C), 15 mm in (D), 5 mm in (Ei), 1 mm in (Eii)–(Eiv), 7.5 mm in enlarged panels of (D), and 0.5 mm in enlarged panels of
(Eiii) and (Eiv). See also Figure S3.(Figure S4). However, localized changes of sphingolipids can
dynamically alter the biophysical properties of membranes
(e.g., membrane curvature, lipid raft assembly, and bilayer
fusion) that are implicated in membrane trafficking (van Blitters-
wijk et al., 2003). To examine sphingolipid changes within endo-
cytic organelles, cell lysates were loaded onto a continuous
OptiPrep gradient and fractionated by high-speed centrifugation1536 Cell Reports 17, 1532–1545, November 1, 2016prior to immunoblotting and liquid chromatography-tandem
mass spectrometry (LC-MS/MS) quantitative analysis of sphin-
golipids (Figure 4).
Consistent with the enlargement of LEs relatively devoid of
contents (Figure 3E), Lamp1 and Rab7 are accumulated in lower
density fractions 3 and 4 upon SK1-I treatment, compared to
control (Figures 4A, S5A, and S5B). Moreover, a modest shift
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Figure 4. SK1-I Accumulates Sphingolipids in
Enlarged LEs
(A–H)WT (A–D) or Sphk1/ (E–H) MEFs were treated
with DMSO or 10 mM SK1-I for 4 hr, followed by
subcellular fractionation. Protein expression was
quantified by immunoblot and presented as percent
enrichment in each fraction. Sphingolipids were
quantified by LC-MS/MS and presented as pico-
moles of lipid per fraction. (A and E) Lamp1. (B and F)
Ceramide. (C and G) Sphingomyelin. (D and H)
Monohexosylceramide. See also Figures S4 and S5.in Rab5 to lower density fractions 7 and 8 by SK1-I is consistent
with the slight enlargement of early endosomes (EEs) (Fig-
ures 3A and S5C). In contrast, the subcellular distribution of
mitochondrial marker Hsp60 is not altered by SK1-I (Figure S5D).
Interestingly, the enlarged LE fraction accumulates ceramide,
monohexosylceramide, and sphingomyelin (fractions 3 and 4;
Figures 4B–4D). Moreover, ceramide and sphingomyelin are
slightly increased in the dilated EE fraction of SK1-I-treated cells
(fractions 7 and 8; Figures 4B and 4C). Surprisingly, sphingosine
does not accumulate in the enlarged LE fraction of SK1-I-treated
cells but rather displays a sharp enrichment in fraction 9, which
overlaps with endosomal and plasma membrane markers and
is consistent with stalled endocytic trafficking (Figures S5E
and S5F).
Despite comparable uptake of the inhibitor (Figure S5G),
Sphk1-deficient MEFs do not exhibit a significant shift in LE
markers to lower density fractions or accumulate sphingolipids
after treatment with SK1-I (Figures 4E–4H and S5H–S5J). Inter-dy
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shifted toward lower density fractions in
vehicle-treated Sphk1/ cells compared
to WT (compare black lines in Figures 4A
and 4E). Moreover, Sphk1-deficient cells
appear to mildly accumulate sphingolipids
under basal conditions (compare the black
lines in Figures 4B–4D versus those in Fig-
ures 4F–4H). It is tempting to speculate
that the loss of Sphk1 alters the lipid profile
of LE/Lys. However, as Sphk1/ MEFs
appear to maintain fluid-phase endocytosis
(Figure 1B), and Sphk1-null mice are viable
with no apparent abnormalities (Allende
et al., 2004), the effect of Sphk1 defi-
ciency on basal endosomal function re-
quires further study. Collectively, these
results demonstrate that SK1-I decreases
S1P, accumulates sphingosine, and in-
duces the Sphk1-dependent accumulation
of sphingosine metabolites in enlarged LEs.
SK1-I Induces Autophagy and Blocks
Autophagic Flux
The endocytic pathway is critical for the
maintenance of autophagic flux (Razi
et al., 2009). Although the accumulation ofsfunctional LEs and amphisomes suggests impaired autopha-
flux, autophagic activity was assessed by immunoblot for
3-II, a widely used marker of autophagosomes, and the
tophagic substrate p62/SQSTM1 (Klionsky et al., 2012). Auto-
agy induction is observed as the increase in LC3-II in the pres-
ce of lysosome inhibitors compared to Lys inhibitors alone.
deed, SK1-I significantly increases LC3-II in the presence of
e lysosomal protease inhibitors E64d, pepstatin A, and leupep-
(E/P/L), compared to E/P/L alone, to indicate induced auto-
agosome formation (Figures 5A and 5B). Autophagic flux
indicated by an increase in LC3-II in the presence versus
sence of Lys inhibitors. Indeed, LC3-II is further accumulated
the presence of Lys inhibitors in SK1-I-treated cells at 6 hr and
hr to indicate induced autophagic flux (Figures 5A and 5C). In
ntrast, autophagic flux is impaired at 12 hr of SK1-I treatment
igures 5A and 5C). The accumulation of p62 and a high-molec-
r-weight p62 oligomer (approximately 250 kDa) at 6 hr and
hr of SK1-I that is unaffected by E/P/L is consistent withorts 17, 1532–1545, November 1, 2016 1537
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Figure 5. SK1-I Induces Autophagy and Blocks Autophagic Flux
(A–D) Atg5+/+ MEFs were treated with DMSO or 10 mM SK1-I for the indicated durations. (A) E64d (10 mM), pepstatin A (10 mg/mL1), and leupeptin (1 mg/mL)
(E/P/L) were added during the final 6 hr of treatment. Lysateswere analyzed by immunoblot for LC3, p62, and b-actin. (B) SK1-I-induced autophagy and (C) SK1-I-
induced autophagic flux were calculated as described in the Experimental Procedures and are presented as mean ± SD from three independent experiments. (D)
Quantification of p62 levels normalized to b-actin. Mean ± SD from three independent experiments.
(legend continued on next page)
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impaired autophagic flux (Figure 5D). In contrast, the restoration
of p62 to basal levels at 24 hr of SK1-I with accumulation
by E/P/L indicates restored autophagic flux (Figure 5D). The
discrepancy in autophagic flux at 6 hr, as determined by LC3-II
and p62, may be due to autophagic flux in the absence of p62-
associated cargo, autophagy-independent regulation of p62,
or altered LC3-II delipidation.
Tandem-fluorescent LC3 (tf-LC3; RFP-EGFP-LC3) was used
as an additional approach to monitor autophagic flux. Auto-
phagosomes (RFP+EGFP+, or ‘‘yellow’’ puncta) and degra-
dative amphisomes/autolysosomes (RFP+EGFP, or ‘‘red’’
puncta) can be distinguished by the pH-sensitive quenching of
EGFP. Consistent with immunoblotting, 6-hr treatment with
SK1-I induces autophagosome formation, as RFP+EGFP+ LC3
puncta are accumulated by SK1-I in the presence of E/P/L
compared to E/P/L alone (Figure 5E). As the phenotype is similar
in cells treated with SK1-I in the presence or absence of E/P/L,
autophagic flux appears to be minimal at 6 hr (Figure 5E). The
accumulation of large RFP+EGFP LC3 structures by SK1-I is
most likely a result of the fusion of previously functional LEs
and amphisomes (Figure 5E). Consistently, prolonged treatment
with SK1-I restores autophagic flux, as SK1-I-treated cells
display an increase in RFP+EGFP LC3 puncta, indicative of
degradative amphisomes/autolysosomes, that is impaired by
lysosomal inhibition (Figure 5F). Collectively, these results
indicate that SK1-I induces autophagosome biogenesis and
dynamically regulates autophagic flux to impair and restore
degradation.
Autophagy Machinery Coordinates with Lys Biogenesis
to Clear Enlarged LEs in Response to Sphk1 Inhibition
To determine the role of autophagy during Sphk1 inhibition, WT
and autophagy-deficient Atg5/ or Atg3/ MEFs were treated
with SK1-I. Atg5 and Atg3 are required for the lipidation of LC3-I
to LC3-II during autophagosome biogenesis. Loss of autophagy
does not alter vacuole formation by SK1-I. However, although
WT cells clear SK1-I-induced vacuoles by 24 hr, vacuoles are
significantly sustained in Atg5- or Atg3-deficient MEFs (Fig-
ure 6A). To verify this result, GFP-Atg5 or mutant Atg5K130R,
which is unable to rescue LC3 lipidation, was stably expressed
in Atg5/ MEFs. Although GFP-Atg5 rescues vacuole clear-
ance, Atg5K130R fails to do so to indicate that LC3 lipidation is
required for clearance (Figure 6B). To assess the role of autopha-
gic flux in vacuole clearance, cells were treated with SK1-I
for 6 hr, followed by the addition of lysosomal protease inhibitors.
Similar to the loss of Atg5 or Atg3, Lys inhibition prolongs
vacuoles in WT cells to suggest that autophagic flux is required
for clearance (Figure 6B).
To examine themechanism of vacuole clearance, MEFs stably
expressing Lamp1-RFP were treated with SK1-I and moni-
tored by time-lapse imaging. During vacuole clearance, small
Lamp1-positive granule-like structures are recruited to the vac-
uole membrane prior to the gradual condensation of vacuoles(E and F) Confocal images of MEFs stably expressing RFP-EGFP-LC3 treated with
6 hr of treatment.
Data are presented as the mean ± SD from three independent experiments. *p <
bars represent 15 mm. See also Figure S6.(Movie S6). This mechanism is distinct from autophagic Lys
reformation in which proto-lysosomal tubules extend and bud
from enlarged Lys (Yu et al., 2010). TEM imaging after vacuole
clearance reveals the accumulation of significantly smaller vesi-
cles containing multi-lamellar membranes (Figure 6C). As the
enlarged LEs were initially devoid of membranes (Figure 3E),
internalization of the limiting membrane appears to lead to vac-
uole shrinkage. Further study is required to uncover the mecha-
nism of this process.
Sphingosine and ceramide have been implicated in the in-
duction of autophagy and regulation of autophagic flux (Young
et al., 2013). To determine whether sphingosine metabolism to
ceramide is required for the autophagy-mediated clearance of
SK1-I-induced vacuoles, ceramide synthase was inhibited by
fumonisin B1 (FB1). Interestingly, FB1 significantly delays the
clearance of SK1-I-induced vacuoles (Figure 6D). Of note, vac-
uole clearance is slightly accelerated in Sphk1+/+ MEFs (12–
20 hr; Figure 6D; data not shown) compared to Atg5+/+ MEFs
(16–24 hr; Figures 6A–6C) to indicate that the precise timing
of vacuole formation and clearance is likely dependent on
genetic background. Importantly, LC3-II is increased upon
co-treatment with SK1-I and FB1 compared to SK1-I alone
(Figure 6E). Moreover, LC3-II accumulation appears to result
from impaired flux, as LC3-II does not further accumulate with
E/P/L. To assess the role of ceramide in the clearance of
Sph-induced vacuoles in Sphk1/ MEFs, cells were treated
with Sph in the presence of FB1. Consistent with SK1-I, inhibi-
tion of ceramide synthase by FB1 accumulates Sph-induced
vacuoles in Sphk1/ MEFs (Figure 6F). A similar autophagic
phenotype is observed where FB1 increases LC3-II in the pres-
ence of Sph compared to Sph alone (Figure 6G). Moreover, FB1
impairs Sph-induced autophagic flux as LC3-II accumulation is
insensitive to E/P/L compared to Sph treatment alone (Fig-
ure 6G). More detailed studies are required to dissect the dual
effects of Sph and Sph metabolites in autophagosome forma-
tion and degradation.
Although lysosomal protease activity is required for the
efficient clearance of SK1-I-induced vacuoles (Figure 6B),
cathepsin B activity is significantly suppressed by SK1-I after a
few hours of treatment (Figure 3B). Therefore, we hypothesized
that new Lys biogenesis may facilitate clearance. Transcription
factor EB (TFEB) is a master regulator of autophagy and Lys-
associated genes (Settembre and Medina, 2015). As lysosomal
Sph can activate TFEB (Ho¨glinger et al., 2015), we examined
TFEB localization during the clearance of SK1-I-induced vacu-
oles. Indeed, TFEB translocates to the nucleus prior to vacuole
clearance (Figures 7A and 7B). Consistently, the expression of
Lamp1 and Rab7, two TFEB target genes, are increased during
vacuole clearance (Figure 7C).
Notably, the nuclear translocation of TFEB in response
to SK1-I is markedly suppressed in Atg5-deficient cells,
which have impaired vacuole clearance (Figures 7A and 7B).
To monitor Lys in Atg5/ MEFs during SK1-I treatment,DMSO or 7.5 mMSK1-I for (E) 6 hr or (F) 16 hr. E/P/L was added during the final
0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, ANOVA. ns, not significant. Scale
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(G) Immunoblot ofSphk1/MEFs pre-treated with 50 mMFB1 for 30min prior to the addition of 10 mMSph for 12 hr.Where indicated, E/P/L was added during the
last 6 hr of treatment.
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See also Movie S6.
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Figure 7. The Clearance of SK1-I-Induced Vacuoles Occurs Concomitantly with the Activation of TFEB-Mediated Lys Biogenesis and Is
Dependent on Atg5
(A) Live-cell fluorescence images of WT and Atg5/ MEFs stably expressing GFP-TFEB treated with 7.5 mM SK1-I for 16 hr. White and yellow dotted lines
represent outlines of nuclei lacking or containing GFP-TFEB, respectively.
(B) WT or Atg5/MEFs were treated with 10 mMSK1-I for 24 hr and fractionated to obtain cytoplasmic (Cyt), nuclear binding proteins (NBP), or insoluble nuclear
proteins (INB). Immunoblot for TFEB, a-tubulin, and poly(ADP-ribose) polymerase (PARP).
(C) WT MEFs were treated with DMSO or 10 mM SK1-I for the indicated time points. Cell lysates were analyzed by immunoblot for Lamp1, Rab7, and b-actin.
(D) WT and Atg5/ MEFs were pulsed with 100 mg/mL AF488-Dex for 1 hr followed by a 2.5 hr chase in dextran-free DMEM to label Lys. Live-cell fluorescent
images of cells treated with DMSO or 10 mM SK1-I for 4 hr followed by MagicRed cathepsin B substrate (MR-CathB).
Scale bars represent 20 mm in (A) and 10 mm in (D).lysosomal compartments were pulse-chase labeled with 10 kDa
Alexa Fluor 488-dextran. Unexpectedly, while the SK1-I-induced
vacuoles of WT cells were labeled by fluorescent dextran, fluo-
rescent dextran was maintained in punctate structures and not
enlarged vacuoles in SK1-I-treated Atg5/ MEFs (Figure 7D).
Loss of Atg5 has been reported to impair the retromer-mediated
retrieval ofmannose-6-phosphate receptor to result in hybrid LE/
Lys (Peng et al., 2014). Although beyond the scope of this paper,
we propose that the hybrid LE/Lys lacks the machinery required
for association with vacuoles for clearance. Given that Lys are
not consumed in Atg5-deficient cells by autophagy, TFEB is
not activated for Lys biogenesis. These results emphasize the
complex crosstalk between the endocytic pathway and auto-
phagy machinery to suggest a potential mechanism for the
clearance of dysfunctional LEs.DISCUSSION
The function of Sphk1 in membrane trafficking appears to be
highly conserved. Here, we provide evidence for the role of
Sph and Sphk1 in endocytic membrane trafficking. Our results
suggest that SK1-I enters the cell via lipid-raft-mediated endocy-
tosis to imply that, like Sph, the inhibitor is largely restricted to
membranes. By overloading endocytic membranes with exoge-
nous Sph or Sph mimetic while inhibiting Sphk1 activity (e.g., by
Sphk1aG82D, SK1-I, or PF-543), Sphk1 is stabilized at LE mem-
branes to promote membrane fusion and reveal a role for Sph
and Sphk1 in endosomal fusion. We believe that small-molecule
inhibitors like PF-543 fail to selectively accumulate Sph and
Sphk1 at endosomal membranes and, thus, do not induce vac-
uoles. While we recognize that our current system is inherentlyCell Reports 17, 1532–1545, November 1, 2016 1541
artificial, we hope that future technologies will aid in monitoring
sphingosine metabolism during dynamic processes such as
endosomal trafficking.
Sph is a fusogenic lipid that can promote bilayer fusion (Castro
et al., 2014; Gon˜i et al., 2014). Moreover, perturbation of the local
membrane environment by Sph can enhance SNARE-mediated
membrane fusion by the direct activation of SNARE proteins
such as synaptobrevin (Darios et al., 2009). Sph also regulates
the electrostatic interaction of vesicles and SNARE vesicle-asso-
ciated membrane protein 2 (VAMP2) by neutralization of nega-
tively charged membranes (Williams et al., 2009). As the core
machinery for membrane fusion in neuronal and endosomal sys-
tems are highly conserved (Antonin et al., 2000), the identifica-
tion of endosomal SNARE proteins as Sph interactors is an
exciting future direction.
Unexpectedly, catalytically inactive Sphk1aG82D enhances the
fusionofLamp1-positivevacuoles inducedbySK1-IorSph tosug-
gest that Sphk1 may promote membrane fusion independent of
catalytic activity. A possible explanation for this result is that
Sphk1aG82D binds endogenous Sph at endocytic vesicles to limit
its metabolism and accumulate the fusogenic lipid. Alternatively,
Sphk1 may facilitate membrane fusion independent of kinase ac-
tivity. Sphk1 assembles dimers that contain a concave, positively
charged groove separating two lipid-binding loop-1 (LBL-1)motifs
(Adams et al., 2016). Docking of Sphk1 dimers to convex, nega-
tively charged membranes orients the LBL-1 motifs to the mem-
brane for substrate extraction with projection of the C terminus
away fromthesurface (Adamsetal., 2016).Notably,LBL-1 is impli-
cated in the curvature-sensitive recruitment of Sphk1 to negatively
chargedmembranesduringendocytosis (Shenetal., 2014) to sug-
gest that dimerization may regulate Sphk1 recruitment to endo-
cyticmembranes.Wepropose that the Sph-mediated recruitment
ofSphk1dimers toendosomalmembranesprimesmembranes for
fusion by acting as amembrane tether and/or recruiting endocytic
factors via its C terminus. As Sph-induced SNARE complex as-
semblywas determined using purified synaptic vesicles, the pres-
ence of Sphk1 cannot be excluded (Darios et al., 2009). Further
investigation is required to test this hypothesis.
Strikingly, vacuoles do not accumulate under basal conditions
in Sphk1/ MEFs. We propose that endocytic sphingolipid
metabolism is tightly regulated to limit Sph accumulation and
protonation during endosomal maturation, leading to membrane
destabilization (Gon˜i et al., 2014). We propose that Sphk2 com-
pensates for Sphk1 to prevent the accumulation of Sph and LE
fusion. While Sphk1-deficient mice lack any apparent abnormal-
ities (Mizugishi et al., 2005), Sphk1/2 double-knockout mice are
embryonic lethal with defective vascularization and highly vacu-
olated endothelial cells (Mizugishi et al., 2005).Whether impaired
endocytic trafficking and/or Sph accumulation contribute to this
phenotype is an interesting avenue for further investigation.
Our results indicate that autophagy, ceramide synthase activity,
and Lys biogenesis aid in the clearance of dysfunctional LEs. First,
SK1-I induces autophagy while dynamically modulating autopha-
gic flux. SK1-I was observed to suppress mammalian target of
rapamycin complex 1 (mTORC1), a well-established negative
regulator of autophagy, thus providing a potential mechanism for
autophagy induction (Figure S6A). Intriguingly, mTOR associates
with sphingolipid-enriched vacuoles to suggest that sphingolipids1542 Cell Reports 17, 1532–1545, November 1, 2016may regulate mTOR localization (Figure S6). Moreover, sphingoli-
pids are established regulators of autophagy (Young et al., 2013),
and the recruitment of Sphk1 to endosomes, autophagosomes,
and amphisomes has recently been linked to autophagosome
biogenesis and degradation (Moruno Manchon et al., 2015,
2016). Additionally, ceramide directly interacts with LC3-II to
mediate cargo recruitment to autophagosomes for efficient
degradation (Sentelle et al., 2012; Dany et al., 2016). We found
that inhibition of ceramide synthase by FB1 impairs autophagic
flux to sustain SK1-I- and Sph-induced vacuoles (Figures 6D–
6G). Further dissection of sphingolipid metabolites and Sphk1 in
the regulation of autophagy is of great interest.
Finally, we demonstrate that Lys biogenesis and restored
autophagic flux coordinate for the clearance of the enlarged
LEs induced by SK1-I. As LysoSensor-positive puncta persist
in the presence of SK1-I-induced vacuoles after a few hours of
treatment (Figure 3C), autophagic flux may temporarily be main-
tained (6 hr; Figure 5C). However, we hypothesize that the
continued induction of autophagy (Figure 5B) and the sequestra-
tion of mTOR at vacuoles (Figure S6B) will deplete the cell of
functional Lys by impairment of mTORC1-dependent autopha-
gic Lys reformation. Consequently, the activation of TFEB for
Lys biogenesis restores autophagic flux and allows for vacuole
clearance by an undetermined mechanism.
Our phenotype is remarkably similar to that observed in
the lysosomal storage disorder Niemann-Pick type C disease
(NP-C). NP-C is a sphingosine storage disease where the lyso-
somal accumulation of Sph impairs calcium storage, leading to
secondary lipid accumulation (Lloyd-Evans et al., 2008). Similar
to our phenotype, NP-C fibroblasts accumulate LEs enriched
in sphingolipids and cholesterol (Sarkar et al., 2014). As Sphk ac-
tivity is suppressed in NP-C (Lee et al., 2014), we propose that a
failure to recruit Sphk to endosomal membranes may drive Sph
accumulation during the pathogenesis of NP-C. Despite func-
tional Lys, NP-C cells have impaired autophagic flux due to the
failure to recruit autophagic SNARE machinery to LEs (Sarkar
et al., 2013). Autophagy induction restores autophagic flux
through the direct fusion of autophagosomes with Lys and has
been proposed as a therapeutic strategy (Sarkar et al., 2013).
Collectively, our studies implicate Sph and Sphk1 in endocytic
membrane trafficking and may contribute to the development
of new therapeutic strategies to restore endocytic membrane
trafficking in sphingolipid storage disorders.
EXPERIMENTAL PROCEDURES
Isolation and Immortalization of MEFs
Sphk1/mice were kindly provided by Dr. Richard Proia (National Institute of
Diabetes and Digestive and Kidney Diseases [NIDDK], NI H) (Allende et al.,
2004). Sphk1/ mice were backcrossed with C57BL/6J mice, and heterozy-
gous mice were intercrossed for MEF isolation from littermate day-12.5 em-
bryos. MEFs were genotyped by PCR amplification of genomic DNA isolated
from the embryo heads, as described previously (Allende et al., 2004). Pas-
sage-two primary MEFs were immortalized by transduction with recombinant
retrovirus encoding simian virus 40 (SV40) large T-antigen and selected by
continuous passage.
Live-Cell Imaging
Cells were seeded in NUNC Lab-Tek II chamber slides (Thermo Scientific) and
imaged in a humidified live-cell chamber equilibrated to 5% CO2 and 37
C
using an Olympus IX81 deconvolution microscope equipped with SlideBook
Software (Version 5.0.0.14, Intelligent Imaging Innovations). To monitor
fluid-phase endocytosis, cells were treated with 0.1 mg/mL Alexa Fluor
488-dextran (10 kDa; Life Technologies). To label acidic organelles, cells
were incubated with LysoSensor DND-189 (1 mM; Life Technologies) accord-
ing to the manufacturer’s protocol. For detection of cathepsin B activity, cells
were incubated withMagicRedCathepsin B (ImmunoChemistry Technologies)
per the manufacturer’s protocol.
Immunofluorescence Imaging
Cells were seeded in NUNC Lab-Tek II chamber slides (Thermo Scientific),
treated as indicated, and fixed with 2% paraformaldehyde in PBS. For immu-
nostaining, cells were permeabilized with 100 mg/mL digitonin in PBS,
washed in PBS, and blocked with 5% normal goat serum prior to primary
antibody incubation overnight followed by secondary antibody for at room
temperature for 1 hr and mounting with ProLong Gold mounting medium (Invi-
trogen). Antibody information is provided in the Supplemental Information.
Confocal images were obtained using a Leica TCS SP8 confocal microscope
(Leica Microsystems) and analyzed using Imaris 3D/4D Image Analysis soft-
ware (Bitplane). All other imaging was performed using an Olympus IX81 de-
convolution microscope. Vacuole size (a.u.; pixels per vacuole) was manually
quantified from differential interference contrast (DIC) images using SlideBook
software. Data are presented as the mean ± SEM.
Electron Microscopy
Cells were seeded on Thermanox coverslips (Electron Microscopy Sciences),
followed by fixation in Karnovsky’s fixative (1.5% paraformaldehyde, 3% glu-
teraldehyde in 0.1Mphosphate buffer, pH 7.3) containing 4.2mM ethylenegly-
col-bis(b-aminoethyl)-N,N,N’,N’-tetracetic acid for 30 min at room tempera-
ture followed by 1 hr at 4C. Cells were washed in 0.1 M phosphate buffer
and 0.1 M sodium cacodylate buffer (pH 7.36) and post-fixed in 1% osmium
tetroxide, 1.5% potassium ferrocyanide in 0.1 M sodium cacodylate buffer
for 30 min at 4C. After thoroughly washing with water, cells were incubated
with 1% uranium acetate at room temperature for 1.5 hr, followed by dehydra-
tion in a graded series of ethanol and propylene oxide. Coverslips were
embedded in Embed 812 resin (Electron Microscopy Sciences), sectioned at
a thickness of 70–90 nm, and mounted on mesh copper grids followed by
staining with uranyl acetate and lead citrate. Images were obtained using a
JEM 1400 digital capture transmission electron microscope (JEOL).
Subcellular Fractionation and Mass Spectrometry
MEFs were treated with DMSO or 10 mMSK1-I for 4 hr, washed twice with ice-
cold PBS, scraped in ice-cold PBS, and pelleted by centrifugation (250 3 g,
4C). Cell pellets were resuspended in 0.9 mL of homogenization buffer
(0.25M sucrose, 140mMNaCl, 1mMEDTA, 20mMTris-HCl [pH 8.0]) contain-
ing protease and phosphatase inhibitors, passed through a 27-gauge syringe,
and centrifuged (5003 g, 4C) to obtain post-nuclear supernatant (PNS). Pro-
tein concentration was determined by bicinchoninic acid (BCA) assay, and
equal amounts of protein were loaded onto 7.2 mL of a continuous 5%–20%
OptiPrep (Sigma-Aldirch D1556) gradient prepared in homogenization buffer.
Samples were centrifuged at 90,0003 g for 20 hr at 4C using a SW-41 swing
rotor. Twelve fractions were collected from the top of the gradient by aspiration
of themeniscus. An aliquot of each fraction was removed for immunoblot anal-
ysis, and the resultant fractions were immediately mixed with ice-cold high
performance liquid chromatography (HPLC)-grademethanol (1:1) and submit-
ted to the Virginia Commonwealth University Lipidomics Core Facility for LC-
MS/MS. Data are presented as the total lipid species (picomoles) per fraction.
Equal volumes of each fraction were analyzed by immunoblot. Expression was
quantified using Image Studio Lite (Version 5.0.21) and presented as the
percentage of protein enrichment in each fraction.
Mass Spectrometry of Cellular Lipids
Cells were seeded in a six-well plate and harvested in 500 mL of ice-cold PBS
containing phosphatase and protease inhibitors. A portion of the cell suspen-
sion was mixed with ice-cold HPLC-grade methanol (3:10) and submitted to
the Virginia Commonwealth University Lipidomics Core Facility for LC-MS/
MS. The remaining cell suspension was sonicated and centrifuged prior toprotein quantification by BCA assay. Data were generated from three repli-
cates and are presented as the mean picomoles per milligram of protein ± SD.
Western Blotting
Cells were washed with ice-cold PBS and scraped in 23 RIPA buffer contain-
ing protease and phosphatase inhibitor cocktails. Nuclear protein isolation
was performed using the QIAGEN Qproteome Nuclear Protein Kit according
to the manufacturer’s protocol, with the addition of phosphatase inhibitors
to all buffers. Proteins were separated by SDS-PAGE and transferred to poly-
vinylidene fluoride (PVDF), as described previously (Young et al., 2012).
Detailed antibody information is provided in the Supplemental Information.
Blots were developed by chemiluminescent substrate (Thermo Scientific) us-
ing the LI-COR C-DiGit Blot Scanner or infrared imaging using the LI-COR Od-
yssey CLx. Immunoblots was quantified using Image Studio Lite (version
5.0.21). LC3-II and p62 were normalized to b-actin, and normalized LC3-II
was used for autophagic calculations, as described previously (Tooze et al.,
2015). In brief, basal autophagic flux was calculated as [(DMSO + E/P/L) 
(DMSO)]; induced autophagy was calculated as [(SK1-I + E/P/L)  (DMSO +
E/P/L)]; and induced autophagic flux was calculated by [(SK1-I + E/P/L) 
(SK1-I)].
Statistical Analysis
Data are representative of at least two independent experiments. Statistical
significance was evaluated by two-tailed Student’s t test or ANOVA with
Tukey’s post hoc test for multiple comparisons using GraphPad Prism soft-
ware. Thresholds of significance are indicated in the figure legends.
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